Abstract:Introduction: Two types of clinical resistance mutations, the C481S mutation, and BTK loss-of-activity mutations, have been identified to covalent (ibrutinib, acalabrutinib, and zanubrutinib) and non-covalent BTK inhibitors (pirtobrutinib). A safe and effective drug to treat patients who relapsed or were refractory to BTK inhibitor treatment is urgently needed. DZD8586 was designed to inhibit both BTK-dependent and BTK-independent BCR signaling pathways, with full blood-brain barrier (BBB) penetration. In the ongoing phase I/II studies (TAI-SHAN1, CTR20220558), DZD8586 demonstrated reasonable pharmacokinetic (PK) properties, safety profiles and preliminary anti-tumor activities in patients with relapsed or refractory (r/r) B-cell malignancies. Methods: The anti-tumor activities of DZD8586 were evaluated in pre-clinical cell and animal models driven by wildtype as well as various mutant BTKs. A healthy volunteer clinical study (TAI-SHAN2, NCT05176873) was conducted to investigate PK, pharmacodynamics (PD), and the safety of DZD8586, offering insight into the drug mechanism of action. The ongoing TAI-SHAN1 study in patients included dose escalation and extension cohorts. Patients with r/r B-NHL who failed systemic therapy were enrolled to determine its recommended phase II dose (RP2D). Different subtypes of B-cell Non-Hodgkin Lymphoma, including chronic lymphocytic leukemia (CLL) who failed BTK inhibitor treatment, central nervous system lymphoma (CNSL), follicular lymphoma (FL), marginal zone lymphoma (MZL) and diffuse large B-cell lymphoma (DLBCL), are eligible. PD biomarkers were assessed. Results: DZD8586 showed equal potencies against wildtype and C481S mutant BTKs, as well as BTK mutations resistant to pirtobrutinib. In healthy subjects, exposure of DZD8586 increased approximately in a dose-proportional manner from 20 mg to 180 mg. Similar PK characteristics were observed between patients and healthy subjects with a half-life of ∼20 h. At the doses of ≥25 mg, near complete inhibition of pBTK was observed. A multinational dose escalation is ongoing. Patient characteristics: histological subtypes: FL, DLBCL, MZL, and MCL; median prior systemic therapies (range): 3 lines (2–6). Preliminary anti-tumor efficacies were observed in multiple B-NHL subtypes starting at 25 mg once daily. No patients experienced ≥ grade 3 treatment-related adverse events, per investigators’ assessment. Conclusion: DZD8586 is a promising investigational drug which could overcome BTK-dependent and BTK-independent resistance. In the ongoing clinical study, DZD8586 showed good safety profile and encouraging anti-tumor efficacy in heavily pre-treated r/r B-NHL patients. The updated data will be presented at the conference. Encore Abstract - previously submitted to ASCO 2023 Keyword: Molecular Targeted Therapies Conflicts of interests pertinent to the abstract Y. Bai Employment or leadership position: Dizal Pharmaceutical K. Fang Employment or leadership position: Dizal Pharmaceutical

Irreversible Dual Inhibitory Mode: the Novel Btk Inhibitor PLS-123 Demonstrates Promising Anti-Tumor Activity in Human B-cell Lymphoma.

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma

A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality with BTK or MDM2-P53 Inhibitor in Diffuse Large B-Cell Lymphoma.

Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.

Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas

Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia

SY-1530, a Highly Selective BTK Inhibitor, Effectively Treats B-cell Malignancies by Blocking B-cell Activation

Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

Design and Synthesis of Novel 1-Substituted 3-(6-phenoxypyridin-3-yl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine Analogs As Selective BTK Inhibitors for the Treatment of Mantle Cell Lymphoma

The Mtor Kinase Inhibitor Everolimus Synergistically Enhances the Anti-Tumor Effect of the Bruton's Tyrosine Kinase (BTK) Inhibitor PLS-123 on Mantle Cell Lymphoma

Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia.

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View

Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies

Treatment of b‐cell malignancies with dzd8586 through overcoming both btk‐dependent and btk‐independent resistance

Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma

Discovery of Pyrazolopyrimidine Derivatives As Potent BTK Inhibitors with Effective Anticancer Activity in MCL.

Design and Synthesis of Novel Substituted Benzyl Pyrrolopyrimidine Derivatives As Selective BTK Inhibitors for Treating Mantle Cell Lymphoma.

Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.

The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Exerts Immunomodulatory Effects Through Regulation of Tumor-Infiltrating Macrophages

Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling